Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: A review
Article first published online: 6 DEC 2007
Copyright © 2007 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Special Issue: Nutrition and Cancer in Children The Second International Workshop, Puebla, Mexico, November 1–5, 2006
Supplement: Puebla Workshop Supplement
Volume 50, Issue Supplement 2, pages 509–516, February 2008
How to Cite
Viana, M. B. and Vilela, M. I. O. P. (2008), Height deficit during and many years after treatment for acute lymphoblastic leukemia in children: A review. Pediatr. Blood Cancer, 50: 509–516. doi: 10.1002/pbc.21396
- Issue published online: 6 DEC 2007
- Article first published online: 6 DEC 2007
- Manuscript Received: 17 SEP 2007
- Manuscript Accepted: 17 SEP 2007
- acute lymphoblastic leukemia;
- height deficit;
There are conflicting data on the incidence and severity of height deficits in children with acute lymphoblastic leukemia (ALL). This is probably due to: (1) collection of data in different phases of treatment; (2) differences in chemotherapeutic regimens; (3) inclusion or not of children who had received cranial irradiation (CRT); (4) limited numbers of patients; (5) relative numbers of prepubertal and pubertal children; (6) different ways of measuring growth deficits. Twenty-five papers published between 1987 and 2006 were reviewed. These reveal that (1) chemotherapy always causes some height reduction during treatment regardless of whether additional CRT is given; (2) catch-up growth occurs immediately after cessation of treatment; (3) intensive chemotherapy alone significantly decreases height in the long-term but to a lesser extent than with additional CRT; (4) young children develop more severe height loss; (5) girls are reported to have greater height deficits but confounding factors have not been adequately considered; (6) late growth hormone (GH) deficiency has been detected in many children, mostly in those who had CRT; (7) GH replacement therapy seems to be effective. ALL relapse in GH-treated children is not more common than in those not treated with GH. Pediatr Blood Cancer 2008;50:509–516. © 2007 Wiley-Liss, Inc.